Latest News

(UroToday.com) There is no molecular imaging agent approved for the initial staging of prostate cancer. Current imaging modalities are suboptimal for the initial staging of men at risk of harboring occult metastatic prostate cancer because of the low positive and negative predictive values of pelvic CT/MRI for detecting regional nodal metastases.1 Because 18F-FDG positron emission tomography […]

(UroToday.com) Globally, prostate cancer is a disease of the aging male, with an average age of diagnosis of 65 years, which increases in prevalence with exposure to screening and diagnostic testing. In high-income countries, prostate cancer is already prevalent and exerting a significant societal burden, with morbidity secondary to disease and treatment. As life expectancy and […]

We are looking for centres to take part in the PRIME Study. The study is brought to you by the team that delivered the PRECISION Study. Background Since the publication of PRECISION, MRI-FIRST, and a number of other high-profile studies, the EAU and other international guidelines panels now recommend performing multiparametric MRI in men when […]

{{header-clinical-trials-navigation}} A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer Condition: Metastatic Prostate Cancer, Prostate Adenocarcinoma Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04446117 Sponsor: Exelixis Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum N/A […]

The EAU is on course for its first online-only Annual Congress: the EAU20 Virtual Congress and Theme Week. Coming up with a suitable scientific programme based on the physical EAU20 was a Herculean task for Scientific Congress Office (SCO) chair Prof. Peter Albers (Düsseldorf, DE) and his team. We spoke with him about the challenges […]

The EAU Section of Infections in Urology (ESIU) is looking for national representatives for the Global Prevalence Study on Infections in Urology (GPIU study). The GPIU study is an international web-based study designed to gather surveillance data on antibiotic resistance, type of urogenital infections, risk factors and data on antibiotic consumption. The annual study is […]

Today marks the launch of the e-course “Metastatic Hormone-Sensitive Prostate Cancer” the 3rd in the series “Advanced Prostate Cancer”.  The European School of Urology (ESU) offers an array of popular digital activities such as these to bolster the knowledge of young and experienced urologists alike. The newly-published e-course covers the definition, classification, and heterogeneity of […]